science wire

« BACK

Pharmacology



Results 351 - 400 of 1468.
« Previous 1 ... 4 5 6 7 8 9 10 11 12 ... 30 Next »


Life Sciences - Pharmacology - 01.11.2018

Pharmacology - Health - 01.11.2018
Roche announces EU approval of Venclyxto plus MabThera for people with previously treated chronic lymphocytic leukaemia
Approval is based on randomised phase III MURANO study showing that fixed duration of treatment with Venclyxto plus MabThera is well tolerated and reduced risk of disease progression or death by 83%

Pharmacology - Health - 01.11.2018
Phase III data showed that Venclexta/Venclyxto plus Gazyva/Gazyvaro reduced the risk of disease worsening or death in people with previously untreated chronic lymphocytic leukaemia with co-morbidities
The phase III CLL14 study compared Venclexta/Venclyxto in combination with Gazyva/Gazyvaro to standard-of-care Gazyva/Gazyvaro plus chlorambucil Data will be submitted to health authorities and prese

Pharmacology - Health - 01.11.2018
Roche to present new data from its industry-leading haematology portfolio at the American Society of Hematology 2018 Annual Meeting
Ten medicines featured in over 70 abstracts, including 25 oral presentations Additional data from three pivotal studies of Hemlibra in people with haemophilia A, with or without factor VIII inhibitor

Pharmacology - Health - 27.10.2018
Two-year data for Novartis brolucizumab reaffirm superiority versus aflibercept in reducing retinal fluid in patients with nAMD
Year two results consistent with previously announced key secondary endpoint data on retinal fluid (IRF and/or SRF) showing superior reductions versus aflibercept   Superior reductions in central sub

Health - Pharmacology - 24.10.2018
Roche announces FDA approval of Xofluza (baloxavir marboxil) for influenza
Roche announces FDA approval of Xofluza (baloxavir marboxil) for influenza First and only single-dose oral medicine approved to treat the flu Xofluza significantly reduced the duration of flu symptom

Pharmacology - Health - 23.10.2018
Novartis announces Lancet publication of pioneering study in migraine prevention showing efficacy of Aimovig where other treatments have failed
The LIBERTY trial is the first study of a CGRP-targeted therapy in a patient population where multiple preventive treatments had previously failed   Patients treated with Aimovig, reported significan

Pharmacology - Health - 22.10.2018
Roche’s Tecentriq plus chemotherapy (carboplatin and Abraxane) as an initial treatment helped people with advanced non-squamous non-small cell lung cancer live significantly longer compared to chemotherapy alone
Roche's Tecentriq plus chemotherapy (carboplatin and Abraxane) as an initial treatment helped people with advanced non-squamous non-small cell lung cancer live significantly longer compared to chemot

Health - Pharmacology - 22.10.2018
Novartis COMBI-AD study of Tafinlar + Mekinist continues to demonstrate relapse free survival benefit in patients with BRAF V600-mutant stage III melanoma
Extended follow up results confirm leading BRAF/MEK inhibitor combination Tafinlar + Mekinist continues to show relapse free survival benefit   Cure rate modeling which estimates fraction of patients

Health - Pharmacology - 21.10.2018
Roche’s investigational personalised medicine entrectinib shrank tumours in people with NTRK fusion-positive solid tumours
Entrectinib showed response irrespective of tumour type or spread to the central nervous system (CNS) Data will be submitted to global regulatory authorities, including the US Food and Drug Administr

Health - Pharmacology - 20.10.2018
Roche’s Tecentriq in combination with Abraxane improves outcomes as an initial treatment for people with PD-L1-positive metastatic triple-negative breast cancer
Tecentriq combination first immunotherapy regimen to demonstrate positive Phase III results in breast cancer Tecentriq and nab -paclitaxel significantly reduced the risk of disease worsening or death in both the intention-to-treat and PD-L1-positive populations Clinically meaningful overall survival improvement in the PD-L1-positive population at this interim analysis Data are being presented at the European Society for Medical Oncology (ESMO) 2

Health - Pharmacology - 19.10.2018
Novartis phase II GEOMETRY mono-1 trial of investigational medicine capmatinib (INC280) shows positive results in patients with MET mutated advanced NSCLC
Novartis phase II GEOMETRY mono-1 trial of investigational medicine capmatinib (INC280) shows positive results in patients with MET mutated advanced NSCLC Phase II study efficacy data showed overall response rate of 72.0% and 39.1%, respectively, in treatment-naive and previously treated patients with advanced MET exon-14 skipping mutated non-small cell lung cancer (NSCLC)   Clinical findings from ongoing study indicate safety prof

Pharmacology - Health - 19.10.2018
Novartis announces presentation of new Lutathera NETTER-1 data
Novartis announces presentation of new Lutathera NETTER-1 data at ESMO demonstrating significant improvement in PFS regardless of baseline liver tumor burden Lutathera treatment was associated with a

Pharmacology - Health - 18.10.2018

Pharmacology - Health - 16.10.2018
Novartis 5-year data in psoriatic arthritis and ankylosing spondylitis reinforces Cosentyx leadership in spondyloarthritis
Data from the MEASURE 1 and FUTURE 1 studies show rapid and long-lasting sustained improvement in the signs and symptoms of ankylosing spondylitis (AS) and psoriatic arthritis (PsA) ,   In rheumatolo

Health - Pharmacology - 15.10.2018
Roche’s Kadcyla reduced the risk of disease recurring in people with HER2-positive early breast cancer with residual disease after neoadjuvant treatment
Phase III KATHERINE study shows Kadcyla significantly improved invasive disease-free survival compared to Herceptin in people with HER2-positive early breast cancer with residual disease after neoadjuvant treatment Data will be submitted to health authorities around the world, including the US Food and Drug Administration and European Medicines Agency Results will be presented at the 2018 San Antonio Breast Cancer Symposium in December Roche tod

Pharmacology - Health - 10.10.2018
Novartis announces new data from the first direct head-to-head trial to demonstrate superior efficacy of Gilenya over Copaxone in patients with relapsing remitting multiple sclerosis
Topline findings from ASSESS show adult relapsing remitting multiple sclerosis (RRMS) patients taking Gilenya (fingolimod) 0.5mg experienced significantly fewer relapses than patients on Copaxone (glatiramer acetate) 20mg   Gilenya 0.5mg is the first and only disease modifying therapy to show superiority in reducing relapses vs Copaxone in a controlled, head-to-head trial   Treatment discontinuations were overall more common in the

Health - Pharmacology - 09.10.2018
Novartis analysis shows crizanlizumab (SEG101) increased the number of patients free of sickle cell pain crises vs placebo during SUSTAIN study
Novartis analysis shows crizanlizumab (SEG101) increased the number of patients free of sickle cell pain crises vs placebo during SUSTAIN study Data published in the American Journal of Hematology show more than twice as many patients taking crizanlizumab did not experience a disease-related pain crisis (also called vaso-occlusive crisis, or VOC) vs placebo   VOCs are the most common, painful complication of sickle cell disease and the main reas

Pharmacology - Health - 08.10.2018
Novartis announces FDA and EMA filing acceptance of siponimod, the first and only drug shown to meaningfully delay disability progression in typical SPMS patients
There is a critical need for safe and effective treatments for secondary progressive multiple sclerosis (SPMS) - a highly debilitating form of MS characterized by gradual, irreversible worsening of d

Health - Pharmacology - 04.10.2018
Positive phase III results for baloxavir marboxil in people at high risk of complications from influenza to be presented at IDWeek 2018
Baloxavir marboxil - a first-in-class, single-dose, investigational oral medicine - is the first potential influenza treatment in clinical trials to demonstrate a clinically meaningful benefit for people highly vulnerable to serious influenza complications CAPSTONE-2 showed that baloxavir marboxil significantly reduced time to improvement of influenza symptoms versus placebo Influenza, or ‘flu', results in millions of debilitating illnesse

Pharmacology - Health - 04.10.2018
FDA approves Roche’s Hemlibra for haemophilia A without factor VIII inhibitors
First medicine to significantly reduce treated bleeds compared to prior factor VIII prophylaxis based on an intra-patient comparison Only medicine that can be self-administered subcutaneously once we

Health - Pharmacology - 04.10.2018
Sandoz Healthcare Access Challenge (HACk) returns, seeking digital solutions to local healthcare access challenges
Despite major advances in modern medicine, universal access to healthcare remains the largest unmet medical need Building on the inaugural Sandoz HACk, this year's competition expands to seek broader

Health - Pharmacology - 03.10.2018
Roche announces new data for risdiplam in Spinal Muscular Atrophy (SMA) at the World Muscle Society Congress
Roche announces new data for risdiplam in Spinal Muscular Atrophy (SMA) at the World Muscle Society Congress Preliminary findings from Part 1 of the FIREFISH study show that infants with Type 1 SMA are meeting developmental milestones including sitting without support Preliminary data from Part 1 of the SUNFISH study show improvements in motor function in people with Type 2/3 SMA No drug-related safety findings leading to withdrawal in risdiplam

Health - Pharmacology - 03.10.2018
Novartis licenses three novel anti-infective programs to Boston Pharmaceuticals
Clinical and pre-clinical stage programs focused on addressing growing need for new treatments against drug resistant Gram-negative bacteria   Agreement is part of Novartis strategy to partner with l

Health - Pharmacology - 24.09.2018
Roche’s investigational medicine entrectinib showed a durable response of more than two years in people with a specific type of lung cancer
Entrectinib reduced tumours in people with ROS1-positive non-small cell lung cancer (NSCLC), including those whose disease had spread to the central nervous system (CNS) Data will be submitted to glo

Health - Pharmacology - 24.09.2018
Roche announces global availability of blood-based genomic profiling test, FoundationOne Liquid
Liquid biopsy test can identify 70 of the most commonly mutated genes in solid tumours, as well as microsatellite instability Many cancer patients have insufficient or inadequate tissue for genomic t

Pharmacology - Health - 18.09.2018
Roche’s NAVIFY decision support portfolio unlocks relevant content from clinical trial and medical publication databases
Roche launches an app ecosystem with the first two clinical decision support apps The apps query globally-renowned resources based on real-world data Patient-specific results lead to more personalise

Health - Pharmacology - 13.09.2018

Pharmacology - Health - 13.09.2018
Novartis announces NEJM publication of landmark PARADIGMS study demonstrating significant benefit of Gilenya in children and adolescents with MS
Treatment with Gilenya (fingolimod) substantially reduced the debilitating impact of MS, with significant decreases in key measures of disease activity vs.

Health - Pharmacology - 13.09.2018
Novartis real-world evidence confirms efficacy and safety benefits of Cosentyx in daily life for psoriasis patients
Real-world evidence confirms Cosentyx efficacy and safety consistent with previously reported clinical studies - Novartis presents a large program of real-world evidence at the 27 th European Academy of Dermatology and Venereology (EADV) Congress, adding to the robust body of clinical data supporting the use of Cosentyx in moderate-to-severe psoriasis - Cosentyx 5-year data in psoriasis from a Phase III study were presented in 2017 , proving lon

Health - Pharmacology - 12.09.2018
Novartis survey shows psoriasis patients want treatment effect beyond clear skin
New patient preference survey confirms that patients value clear skin the most, but expect additional benefits from their treatment, such as proven long-term efficacy and safety data and no injection site reactions A separate ranking incorporating additional characteristics showed that effectiveness in treating multiple manifestations of psoriatic disease was also important The number of injections per dose and injection frequency were least imp

Health - Pharmacology - 10.09.2018
How medicine literally gets under your skin
How medicine literally gets under your skin
If drugs are to enter the body painlessly and efficiently, they can be administered via skin patches.

Pharmacology - Life Sciences - 07.09.2018
Using biosensors to deliver personalized doses of antibiotics
A team of eight EPFL students won the technical prize in the SensUs international competition, designing a portable biosensor that can measure the amount of vancomycin in a patient's blood stream, enabling doctors to better control the dosage and reduce harmful side effects.

Health - Pharmacology - 06.09.2018
Roche to present new data from its extensive lung cancer programme at the 2018 World Conference on Lung Cancer (WCLC)
Roche to present new data from its extensive lung cancer programme at the 2018 World Conference on Lung Cancer (WCLC) New and updated pivotal data from the TECENTRIQ lung programme, including overall

Health - Pharmacology - 04.09.2018
Birmingham and Nankai Universities hold first green economy research forum
University of Birmingham women's cancer expert Dr Sudha Sundar has been chosen as the President-Elect of the British Gynaecological Cancer Society (BGCS) - the first female gynaecological oncologist to be elected to this post.

Health - Pharmacology - 29.08.2018
European Commission approves Novartis combination therapy Tafinlar + Mekinist for adjuvant treatment of BRAF V600 mutation-positive melanoma
Approval based on COMBI-AD study demonstrating greater than 50% reduction in risk of disease recurrence or death in stage III melanoma patients    More than 50% of stage III melanoma patients are lik
« Previous 1 ... 4 5 6 7 8 9 10 11 12 ... 30 Next »

This site uses cookies and analysis tools to improve the usability of the site. More information. |